针对新诊断的多发性骨髓瘤的新药组合:我们如何改进目前的治疗方案?
Sofía Isabel Quezada-Ramírez1, Luz Del Carmen Tarín-Arzaga1, Andrés Gómez-De León1
1Hematology Service, Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León (UANL), Monterrey, Nuevo León, México.
在一线多发性骨髓瘤 (MM) 治疗中实现深度反应至关重要. 早期使用新型免疫调节剂和抗CD38抗体等强效疗法可以改善新诊断患者的结果并延迟复发.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
背景情况:
- 多发性骨髓瘤 (MM) 治疗已在免疫调节剂和抗CD38抗体方面取得显著进展.
- 尽管有进展,但复发仍然是一个挑战,在初始治疗中需要更深入的反应.
研究的目的:
- 审查当前的MM疗法,探索新的药物组合和生物标志物驱动的策略.
- 为了提高新诊断的多发性骨髓瘤 (NDMM) 患者的疗效和耐受性.
主要方法:
- 对元分析,原创文章和现实世界的研究进行系统审查.
- 在PubMed,Scopus和Google Scholar的文献搜索,直到2025年2月.
主要成果:
- 最小残留疾病评估是指导治疗和改善结果的关键.
- 早期的强效疗法,包括下一代抗CD38抗体和CELMoDs,显示出更深入,更持久的反应的前景.
- 正在研究两种特异性抗体和CAR-T细胞等一线免疫疗法,重点是管理传染性并发症.
结论:
- 个性化,生物标志物驱动的方法和新药组合对于完善MM治疗至关重要.
- 早期应用强效疗法和免疫疗法可以显著改善患者的治疗结果,并延迟疾病的进展.
更多相关视频
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy
Drug Therapy
Antianxiety Medications
